|
The significant advantages of the new DirectHaler™nasal delivery principle are:
-
Enables nasal delivery of fine particles – for improved absorption and targeted delivery
-
Prevents risk of pulmonary deposition
-
Prevents risk of immediate dose swallowing
-
Reduces taste impact from nasal dose
Introducing the new nasal delivery principle
When air is being blown out of the mouth against a resistance, the airway passage between the oral and nasal cavities automatically closes. The same reflex is activated when a person blows up a balloon; none of the air escapes through the nose.
This anatomical feature is activated when the patient uses DirectHaler™ Nasal for blowing their nasal dry-powder dose into their nostril. Thus, the dose is captured in the nasal cavity, where it is intended to act or to be absorbed into the systemic circulation. After completion of the dose delivery blow, the nasal/oral connection returns to its normal open state.
Potential for wide application of the proprietary delivery principle
This delivery method holds the potential to become the dominant delivery principle in nasal drug delivery. Direct-Haler A/S is the first drug delivery company to take advantage of this device-dependent reflex for enhancing nasal drug delivery. Naturally, the increased interest in this principle for enhanced nasal delivery has recently led other companies to seek exploitation of the same delivery principle. However, Direct-Haler A/S has broadly issued device and delivery method patents for this area. Patents are issued in more than 40 countries, with priority dates going back to 1997.
|
